Elanco Animal Health

Healthcare · Drug Manufacturers - Specialty & Generic

22.90$ +1.7% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Income Statement

Elanco Animal Health (ELAN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,368 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ELAN
Line item	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	2,914	719	719	697	754	736	770	761	799	731	782	771	787	658	586	890	1,140	1,242	1,279	1,131	1,113	1,226	1,175	1,026	988	1,257	1,057	1,068	1,035	1,205	1,184	1,030	1,020	1,193	1,241	1,137	1,144	1,371	1,368	5,020
Cost of Revenue	1,333	343	343	376	405	409	481	419	463	393	405	411	462	384	345	537	760	716	680	643	651	646	617	600	578	628	570	627	654	648	626	625	631	637	664	530	694	586	570	2,380
Gross Profit	1,505	376	376	321	349	327	289	343	337	338	376	360	326	273	241	352	380	526	599	488	462	580	558	426	410	629	487	441	381	557	558	405	389	556	577	607	450	785	798	2,640
Research & Development	266	64	64	62	62	65	61	59	61	64	69	70	67	67	59	88	113	89	94	94	92	81	82	78	80	81	81	86	79	87	89	87	81	94	92	89	93	97	92	371
Selling, General & Administrative	1,051	–	516	256	259	180	186	179	185	181	201	192	186	182	163	278	182	348	385	342	81	320	343	298	102	327	353	313	85	337	354	323	300	341	400	351	338	381	449	1,519
Total Operating Expenses	2,630	410	410	308	319	245	253	238	246	245	270	262	253	249	222	366	487	437	479	436	419	404	425	376	383	408	434	399	371	424	443	410	381	435	492	580	431	478	689	2,178
Operating Income	283	63	63	13	30	82	37	105	91	93	107	98	72	25	19	-14	-107	89	120	52	43	176	133	50	27	221	53	42	10	133	115	-5.0	8.0	121	85	27	19	307	109	462
Interest Expense	30	–	0.0	0.0	30	30	30	8.6	21	21	21	19	19	23	25	48	61	179	67	60	83	55	68	60	65	68	103	72	67	66	65	85	62	53	70	52	91	57	59	259
Pre-Tax Income	-22	-34	-34	-9.1	-155	78	-40	79	-2.2	45	50	-13	-4.3	-68	-77	-209	-318	-80	-236	-130	-119	75	-14	-44	-88	108	-79	-1,097	-127	12	-32	559	-51	60	25	-50	-259	87	56	-166
Income Tax Expense	26	30	30	12	6.1	4.8	23	19	-19	13	14	-23	5.2	-19	-24	-74	4.7	-19	-26	-26	-15	24	-4.0	21	-34	5.0	18	-1.0	14	-20	18	195	-43	-7.0	14	-16	17	30	2.0	33
Net Income	-48	-64	-64	-21	-162	73	-63	60	16	32	36	10	-9.5	-49	-53	-135	-323	-61	-210	-104	-104	51	-10	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.0	67	11	-34	-276	57	54	-199
EBITDA	–	141	141	88	117	152	35	152	93	149	140	85	98	36	29	-29	-35	301	1.0	100	138	306	225	183	146	349	201	-852	111	244	195	814	175	274	264	178	6.0	316	274	774

LTM = last twelve months (sum of the four most recent quarters).

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings